FDA Grants Rapid AI Clearance Of AI Module For Detection Of Hemispheric Subdural Hematomas  

RapidAI, which is focused on artificial intelligence (AI) in clinical decision-making and workflow, said the FDA granted clearance for Rapid SDH, its AI-powered module for detection and notification of suspected hemispheric acute and chronic subdural hematoma. The module will be available through the company’s Rapid platform. The new module works with Rapid ICH and Rapid Hyperdensity, and together the three modules comprise RapidAI’s hemorrhagic and trauma care AI solution.;;

Rapid SDH uses AI and information gathered from analyzing hundreds of scans to assist neurocritical care teams identify suspected hemispheric subdural hemorrhage faster and with . . .